Plain-English translation of NCT06767254 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are using machine learning—a type of artificial intelligence—to better understand multiple myeloma and predict which patients are most likely to experience early disease relapse. By combining your clinical information, genetic data, and imaging results, doctors hope to create smarter models that can identify high-risk patients upfront. This could help guide personalized treatment decisions and improve outcomes.
Although myeloma treatments have improved dramatically, many newly diagnosed patients still experience early relapse within the first year, and doctors currently don't have reliable ways to identify who those patients are ahead of time. This study aims to use advanced AI technology to spot patterns in patient data that predict who is at highest risk, so doctors can offer more targeted, personalized care.
You likely qualify if…
You likely don't qualify if…
As a participant, you would contribute your clinical records, genetic information, and imaging data to the research database. The study team will analyze this information using machine learning to look for patterns linked to early relapse. You are not receiving any new medication as part of this study—rather, your existing medical information is being used to help develop better prediction tools for future myeloma patients.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
Italy
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment target
~200 participants
Started
October 2024
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Elena Zamagni, MD, PhD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.